Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
Completed · Phase 2
Conditions studied: Prostatic Neoplasms
In brief
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.
Key facts
- Study ID
- NCT00031187
- Run by
- Seagen Inc.
- People needed
- 160
- Starts
- 2000-10-01
- Expected to finish
- 2003-07-01
- Last updated by the study team
- 2011-10-24
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Arizona Cancer Center — Tucson, Arizona, United States
- Highlands Oncology Group — Springdale, Arkansas, United States
- West Los Angeles - VA Healthcare Center — Los Angeles, California, United States
- VA Medical Center of Palo Alto — Palo Alto, California, United States
- Sharp HealthCare, Sidney Kimmel Cancer Center — San Diego, California, United States
- Bendheim Cancer Center — Greenwich, Connecticut, United States
- Broward Oncology Associates — Fort Lauderdale, Florida, United States
- Florida Cancer Specialists — Fort Myers, Florida, United States
- Innovative Medical Research of South Florida — Miami Shores, Florida, United States
- St. Joseph Mercy Oakland Hospital — Pontiac, Michigan, United States
- Arlington Fairfax Hematology-Oncology, P.C. — Arlington, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.